Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University of Utah | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To assess the proportion of women who use HERC for ≥2 years of duration
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| HERC | Women who had an insertion of HERC (Mirena IUD, ParaGard IUD, Implanon or Nexplanon) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Mirena (Levonorgestrel IUS, BAY86-5028) | Drug | Levonorgestrel-releasing intrauterine device 20 mcg/day |
|
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of women who use HERC | 2 years post-HERC initiation |
| Measure | Description | Time Frame |
|---|---|---|
| Duration of real world use of three different HERC devices | 2 years post-HERC initiation |
| Measure | Description | Time Frame |
|---|---|---|
| Difference in patient characteristics of women who chose different HERC devices | 2 years post-HERC initiation | |
| Proportion of HERC used for ≥3 years of duration | ≥3 years post-HERC initiation | |
Inclusion Criteria:
-Women who had an IUD or contraceptive implant inserted and removed within the University of Utah from January 1, 2004 to October 31, 2012
Not provided
Not provided
Women who had an IUD or contraceptive implant inserted at the University of Utah healthcare system
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bayer Study Director | Bayer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Salt Lake City | Utah | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| Background | Sanders J, Turok D, Gawron L, Law A, Wen L, Lynen R. Continuation of Long-Acting Reversible Contraception at Two Years in a University Healthcare Setting: A Retrospective Review. JMCP 2016;22(4a):S126 | ||
| 28188772 | Result | Sanders JN, Turok DK, Gawron LM, Law A, Wen L, Lynen R. Two-year continuation of intrauterine devices and contraceptive implants in a mixed-payer setting: a retrospective review. Am J Obstet Gynecol. 2017 Jun;216(6):590.e1-590.e8. doi: 10.1016/j.ajog.2017.02.003. Epub 2017 Feb 8. | |
| Result | Sanders J, Turok D, Gawron L, Law A, Wen L, Lynen R. Three-Year Continuation of Long-Acting Reversible Contraceptive methods in a Mixed-Payer Health Care Setting: A Retrospective Review. Contraception 2016;94:405-406. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D016912 | Levonorgestrel |
| C044815 | etonogestrel |
| ID | Term |
|---|---|
| D009644 | Norgestrel |
| D009652 | Norpregnenes |
| D009650 | Norpregnanes |
| D009654 | Norsteroids |
| D013256 |
Not provided
Not provided
Not provided
Not provided
Not provided
| ParaGard | Drug | Copper T380A |
|
| Implanon/Nexplanon | Drug | Etonorgestrel contraceptive implant |
|
| Model the predictors of ≥3 years of duration |
| ≥3 years post-HERC initiation |
| Steroids |
| D000072473 | Fused-Ring Compounds |
| D011083 | Polycyclic Compounds |